Clinical Report: DPP-4 inhibitors may have specific autoimmune risks
Overview
Dipeptidyl peptidase–4 inhibitors (DPP-4i) are associated with increased risks of certain autoimmune diseases compared to other diabetes medications. This study utilized electronic health record data to analyze the incidence of autoimmune conditions among patients with type 2 diabetes treated with DPP-4i, GLP-1 receptor agonists, and SGLT2 inhibitors.
Background
The safety profile of diabetes medications, particularly regarding autoimmune conditions, is an important consideration in treatment selection. DPP-4 inhibitors are commonly used in managing type 2 diabetes, but their potential association with autoimmune diseases remains inadequately understood.
Data Highlights
| Comparison | Autoimmune Condition | Risk Ratio |
|---|---|---|
| DPP-4i vs. GLP-1 RA | Dermatomyositis | 2.18 |
| DPP-4i vs. GLP-1 RA | Bullous Pemphigoid | 1.78 |
| DPP-4i vs. SGLT2i | Dermatomyositis | 2.03 |
| DPP-4i vs. SGLT2i | Bullous Pemphigoid | 2.07 |
| DPP-4i vs. SGLT2i | Giant Cell Arteritis | 1.83 |
Key Findings
- DPP-4 inhibitors were associated with a higher likelihood of dermatomyositis and bullous pemphigoid compared to GLP-1 receptor agonists.
- Compared to SGLT2 inhibitors, DPP-4 inhibitors also showed increased risk for dermatomyositis and bullous pemphigoid.
- Lower likelihood of psoriasis and autoimmune thyroiditis was observed with DPP-4 inhibitors compared to both GLP-1 receptor agonists and SGLT2 inhibitors.
- No significant differences were found for negative control outcomes between the drug classes.
- The study's observational design may introduce biases and confounding factors affecting the results.
Clinical Implications
Clinicians should be aware of the potential autoimmune risks associated with DPP-4 inhibitors when prescribing these medications.
Conclusion
The study highlights important safety signals regarding DPP-4 inhibitors and their association with certain autoimmune diseases.
Related Resources & Content
- ACR Open Rheumatology, ACR Open Rheumatology, 2023 -- Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes
- MDSpire News — GLP-1 RAs Associated With Small ION Risk Increase
- MDSpire News — GLP-1 Drugs Lower Death and Heart Risks in Patients With Inflammatory Diseases and Diabetes
- MDSpire News — Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?
- Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
- Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis
- Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
